Viridian Therapeutics, Inc./DE Selling and Marketing Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Selling and Marketing Expense of $1.67 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE selling and marketing expense for the quarter ending 2016-12-31 was $231.00K, a 69.40% decline year-over-year.
- Viridian Therapeutics, Inc./DE selling and marketing expense for the quarter ending 2016-09-30 was $373.00K, a 53.14% decline year-over-year.
- Viridian Therapeutics, Inc./DE selling and marketing expense for the quarter ending 2016-06-30 was $555.00K, a 3.31% decline year-over-year.
- Viridian Therapeutics, Inc./DE selling and marketing expense for the quarter ending 2016-03-31 was $510.00K, a 17.51% increase year-over-year.
- Viridian Therapeutics, Inc./DE selling and marketing expense for fiscal 2016 was $1.67M, a 34.78% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE selling and marketing expense for fiscal 2015 was $2.56M, a 256.90% increase from fiscal 2014.
- Viridian Therapeutics, Inc./DE selling and marketing expense for fiscal 2014 was $717.00K, a 105.44% increase from fiscal 2013.
- Viridian Therapeutics, Inc./DE selling and marketing expense for fiscal 2013 was $349.00K.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $604.00K derived: sum of 2 quarters · filed 2017-03-24 | $1.16M derived: sum of 3 quarters · filed 2017-03-24 | $1.67M 10-K · filed 2017-03-24 | |||
| 2016-09-30 | $373.00K 10-Q · filed 2016-10-26 | $928.00K derived: sum of 2 quarters · filed 2016-10-26 | $1.44M 10-Q · filed 2016-10-26 | $2.19M derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2016-06-30 | $555.00K 10-Q · filed 2016-08-15 | $1.06M 10-Q · filed 2016-08-15 | $1.82M derived: sum of 3 quarters · filed 2017-03-24 | $2.62M derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2016-03-31 | $510.00K 10-Q · filed 2016-05-16 | $1.26M derived: sum of 2 quarters · filed 2017-03-24 | $2.06M derived: sum of 3 quarters · filed 2017-03-24 | $2.63M derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2015-12-31 | $755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $1.55M derived: sum of 2 quarters · filed 2017-03-24 | $2.13M derived: sum of 3 quarters · filed 2017-03-24 | $2.56M 10-K · filed 2017-03-24 | |||
| 2015-09-30 | $796.00K 10-Q · filed 2016-10-26 | $1.37M derived: sum of 2 quarters · filed 2016-10-26 | $1.80M 10-Q · filed 2016-10-26 | $2.22M derived: sum of 4 quarters · filed 2016-10-26 | |||
| 2015-06-30 | $574.00K 10-Q · filed 2016-08-15 | $1.01M 10-Q · filed 2016-08-15 | $1.42M derived: sum of 3 quarters · filed 2016-08-15 | $1.59M derived: sum of 4 quarters · filed 2016-08-15 | |||
| 2015-03-31 | $434.00K 10-Q · filed 2016-05-16 | $850.00K derived: sum of 2 quarters · filed 2016-05-16 | $1.02M derived: sum of 3 quarters · filed 2016-05-16 | $1.08M derived: sum of 4 quarters · filed 2016-05-16 | |||
| 2014-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $585.00K derived: sum of 2 quarters · filed 2016-03-21 | $651.00K derived: sum of 3 quarters · filed 2016-03-21 | $717.00K 10-K · filed 2016-03-21 | |||
| 2014-09-30 | $169.00K 10-Q · filed 2015-11-13 | $178.82K 10-Q · filed 2014-11-14 | $235.00K derived: sum of 2 quarters · filed 2015-11-13 | $301.00K 10-Q · filed 2015-11-13 | $325.64K 10-Q · filed 2014-11-14 | $396.91K derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $66.00K 10-Q · filed 2015-08-14 | $73.75K 10-Q · filed 2014-08-14 | $132.00K 10-Q · filed 2015-08-14 | $146.82K 10-Q · filed 2014-08-14 | $227.91K derived: sum of 3 quarters · filed 2015-08-14 | $327.85K derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | $66.00K 10-Q · filed 2015-05-15 | $161.91K derived: sum of 2 quarters · filed 2015-05-15 | $261.85K derived: sum of 3 quarters · filed 2015-05-15 | $328.90K derived: sum of 4 quarters · filed 2015-05-15 | |||
| 2013-12-31 | $95.91K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $195.85K derived: sum of 2 quarters · filed 2015-03-27 | $262.90K derived: sum of 3 quarters · filed 2015-03-27 | $349.00K 10-K · filed 2015-03-27 | |||
| 2013-09-30 | $99.94K 10-Q · filed 2014-11-14 | $166.99K derived: sum of 2 quarters · filed 2014-11-14 | $253.09K 10-Q · filed 2014-11-14 | ||||
| 2013-06-30 | $67.05K 10-Q · filed 2014-08-14 | $153.15K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |